Very very good post.IMO worth a re post.
A nice read for new investors, and they seem to be showing up and accumulating on a regular basis these days.
Couch Member Level Sunday, 03/01/15 10:02:53 AM
Re: mrwrn2010 post# 146719
Post # of 146757
Quote:
It is my honest opinion that Elite is very much under the radar as well as mostly doubted by the investment community. Once this Phase 3 trial starts, Elite will be the farthest they have ever been in their ART development. Last time we stopped right at the verge of a Phase 3. This time it's different.
Exactly and I agree on all accounts. Previously, as you mention Elite was given the green light for a Phase III trial on their once daily ADT Oxy/Nal Eli 216 opioid only to not initiate this trial for lack of funds. Disappointing to say the least because back then there was no once daily Oxy on the market let alone an ADT version. Now Purdue has a once a day ADT opioid on the market beating Elite to the punch.
The difference is Elite now has the funding in place and this efficacy trial is much shorter in duration and with about half the participants. 150 subjects for Eli 200 versus the 300 for their Eli 216 product.
As you also point out once this trial is initiated Elite will have moved the farthest they have ever been with their ART development. Combine this with the strongest revenue generating products and income Elite has ever had historically and hat Elite is continuing to clean up past managent messes - such as becoming cash flow off of operations and removing the ongoing concern from their SEC filings, putting up an impressive new website, expanding their Northavale facility and buying more manufacturing equipment, having working capital and cash on hand, hired new upper management to support the launch of Eli 200 and 201, and planning on getting to the Nasdaq around 2016 organically- AND you have the structure in place to become the pharmaceutical company Atul Mehta (the founder of Elite) envisioned to begin with. Something investors can be proud of.
I don't think you could ask for more at this point. In essence, file their first NDA and start the PR machine to get Elite above the radar once again. As in times past, by putting these various measures in place now and following through on them and giving them time to mature, in a year or two larger institutional investors will come back and that is when the real money comes IMO.
My only ongoing assumption/concern from this point forward is for the company continue to manage the dilution while increasing shareholder value. So far since Nasrat has come on board the company has manged this difficult tightrope impressively to the dismay of the few naysayers here
